Purespring Therapeutics

About:

Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.

Website: https://purespringtx.com/

Twitter/X: PURESPRINGTX

Top Investors: British Patient Capital, Sofinnova Partners, Forbion Capital Partners, Gilde Healthcare, Syncona Partners LLP

Description:

Purespring Therapeutics is a pioneering company focused on developing gene therapies for various kidney diseases, particularly targeting podocytes, which are specialized kidney cells. The company is among the first globally to employ AAV gene therapy specifically for kidney conditions, aiming to tackle one of the most challenging areas in medicine.

Total Funding Amount:

125M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2020-01-01

Contact Email:

contact(AT)purespringtx.com

Founders:

Mauro Giacca, Moin Saleem

Number of Employees:

11-50

Last Funding Date:

2024-10-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai